Quay Pharma is an independent, privately owned contract development manufacturing organisation (CDMO). Since 2002 we have proudly delivered over 250 successful projects and exercised continued improvement whilst remaining true to our core values. Our use of proven manufacturing technologies provides a low economic risk and fast entry in to first in human trials, and its elevated scale-up to future clinical phases. We have knowledge and expertise in the formulation and development of a wide range of product formats and dosage forms for modified and targeted release within the body. We are licensed for the clinical and commercial manufacturing of new chemical entities, biologicals and live biotherareutics in a non-sterile environment. Our core strength is our people, we invest in the best, only experts with strong scientific backgrounds underpins the service we deliver.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
We continually develop pharmaceutical products with world-leading expertise that support safety, quality and commercial viability. We innovate and challenge ourselves to be the very best in our field.
At Quay Pharma our job is not simply to find an effective method of drug delivery for each new product, it is to find the best and most effective method possible.
Our comprehensive, flexible range of services enables clients to bring drug products through the various stages of clinical development; from pre-formulation work to formulation, dosage form design and optimisation.
From our GMP facilities we can extend this into full manufacturing and packaging support for Phase I, Phase II and small-scale Phase III trials. Quay Pharma also provide a fully-integrated service for the development and manufacture of specials, an acutely important area of medicine. Our outstanding analytical services team will support projects throughout their progress.
Quay Pharma’s team of scientists works under the direction of Chairman Professor Mike Rubinstein and Chief Scientific Officer Professor John Collet, who each have over 30 years hands on experience. Together, the team represents an exceptional depth of pharmaceutical development knowledge, accumulated through many years work in academia and industry.
Every project benefits from our robust project management as well as our technical proficiency. Offering advice and development for all dosage forms and drug types, we have particular expertise in developing products for oral or topical delivery including; tablets, capsules, liquids, gels and creams. From traditional small molecules to proteins, peptides and larger biological agents, Quay Pharma can work with substances of all types, in all therapeutic areas.
Particular satisfaction we derive from the more challenging projects, such as finding effective delivery methods for drugs that exhibit poor solubility and bioavailability or which require a modified or controlled release and have a strong record of success in solving the more difficult problems.
We believe in direct communication, honest dialogue, and collaborative working. Confidentiality is absolutely assured in every aspect of our service, from your first enquiry onwards.
We understand the importance of costs and timelines, and make sure that these factors are clearly set out and agreed at the outset.
While our aim is to meet your immediate requirements, we always look ahead to ensure that the short-run manufacturing we do can easily be scaled to commercial quantities or licensed to another party.
Our working practice is to agree a fee for each stage of our service, in advance. We will not tie you in to formulations or technologies that will reduce your future options. Our work, once paid for, is yours without further commitment.
The Quay Pharma Process, Stage by Stage:
1: We carry out a collaborative research and analysis project, to investigate the parameters and scope of the project and explore the contribution we can make. All of the work, even at this initial stage before you incur any costs, is absolutely confidential.
2: We prepare a proposal setting out the scope of the work we propose to do, the milestones we will meet along the way, the deliverable outcomes, the costs and the schedules. At this stage, we will make it clear where the various responsibilities lie, and whether we need any further information or assurances from you.
3: We sign a technical agreement with you, defining the work we will do and the setting out deliverables, milestones, timelines, schedules and costs. This is the first stage at which you make any commitment to us.
4: We manage the project according to the agreement, and at each milestone we report back to you, review the work we’ve done and agree on the next stage.
Our scientific expertise is outstanding, and widely acknowledged. Our team is highly regarded in the pharmaceutical industry for their exceptional knowledge of dosage form development, formulation technologies and drug delivery systems.
We genuinely enjoy solving problems. We are excited and motivated by the most intractable challenges, and take particular pleasure in finding effective responses where other companies have failed.
We are flexible. Our working practices are completely integrated with our formulation, analytical and manufacturing teams working in close partnership with each other. Unlike the large generic contract organisations, we can and do adapt to the requirements of each new client and project.
Every project is unique. We do not believe in offering generic products that tie clients in to platform technologies or particular manufacturers. We talk at length with our clients to make sure we understand the challenges and problems that they face, then we conduct an extensive research exercise before developing an individual and precisely tailored proposal.
We don’t retain Intellectual Property rights, and we don’t charge royalties. Many organisations will levy an extra charge if you insist on knowing the composition of a formulation they have produced for you. We will not, and neither will we tie you in to a proprietary manufacturing process.